US Stock Market Move | BEIGENE (ONC.US) rises more than 3%, overseas authorization total for China's innovative drugs in the first quarter hits a new high.

On Wednesday, BEIGENE (ONC.US) rose more than 3%, to $252.97. It is understood that with the improvement of research and development capabilities of domestic innovative drug companies, more and more companies are entering the international market. In particular, the amount of outbound licensing transactions of Chinese innovative drugs has surged. In 2024, the overseas licensing initial payment reached $3.16 billion, with a total transaction amount of $51.1 billion. Large-scale licensing transactions such as UNITED LAB and Jiangsu Hengrui Pharmaceuticals have set new records, and the global BD transaction ratio has increased to 30%. In the first quarter of 2025, the total amount of overseas licensing set a new record of $45.5 billion and is close to the level of the entire year of 2024. Additionally, on July 1st, the National Medical Insurance Administration, together with the National Health Commission, issued "Several Measures to Support the High-Quality Development of Innovative Drugs", once again emphasizing comprehensive policy support for innovative drugs, and incorporating commercial insurance into the system framework, opening up long-term payment space for innovative drugs.